成人创伤性脑损伤患者的抗癫痫发作药物:系统评价与贝叶斯网络Meta分析
该系统评价与贝叶斯网络Meta分析检索MEDLINE、Embase、PubMed、Cochrane CENTRAL与LILACS(自建库至2023年10月),纳入10项随机对照试验共1851例成人创伤性脑损伤患者,评估任何抗癫痫发作药物对早期(7天内)癫痫发作的影响。与安慰剂相比,苯妥英(RR 0.28,95%CrI 0.13-0.57,中等确定性)和左乙拉西坦(RR 0.20,95%CrI 0.07-0.60,中等确定性)与早期癫痫发作风险降低相关;卡马西平可能相关但证据非常不确定(RR 0.41,95%CrI 0.12-1.27,非常低确定性),丙戊酸可能几乎无差异但证据非常不确定(RR 0.97,95%CrI 0.16-9.00,非常低确定性)。任何抗癫痫发作药物对晚期癫痫发作或全因死亡率的影响证据非常不确定。作者结论认为苯妥英或左乙拉西坦可降低成人创伤性脑损伤患者的早期癫痫发作风险,需进一步研究评估所需疗程与长期安全性。
要点
- 成人创伤性脑损伤患者中,与安慰剂相比,苯妥英降低早期(7天内)癫痫发作风险(RR 0.28,95%CrI 0.13-0.57,中等确定性)。
- 与安慰剂相比,左乙拉西坦降低早期癫痫发作风险(RR 0.20,95%CrI 0.07-0.60,中等确定性)。
- 卡马西平可能降低早期癫痫发作风险,但证据非常不确定(RR 0.41,95%CrI 0.12-1.27,非常低确定性)。
- 丙戊酸对早期癫痫发作风险可能几乎无差异,但证据非常不确定(RR 0.97,95%CrI 0.16-9.00,非常低确定性)。
- 任何抗癫痫发作药物对晚期癫痫发作或全因死亡率的影响证据非常不确定。
适用人群与场景
- 成人创伤性脑损伤患者,纳入随机对照试验,比较任何抗癫痫发作药物与安慰剂或另一种药物。
研究设计与关键结果
- 研究类型:系统评价与贝叶斯网络Meta分析,纳入10项随机对照试验,共1851例成人创伤性脑损伤患者;检索MEDLINE、Embase、PubMed、Cochrane CENTRAL与LILACS,自建库至2023年10月。
- 主要结局:早期癫痫发作(7天内)。与安慰剂相比,苯妥英RR 0.28(95%CrI 0.13-0.57,中等确定性);左乙拉西坦RR 0.20(95%CrI 0.07-0.60,中等确定性);卡马西平RR 0.41(95%CrI 0.12-1.27,非常低确定性);丙戊酸RR 0.97(95%CrI 0.16-9.00,非常低确定性)。
- 次要结局:晚期癫痫发作与全因死亡率,在最长报告随访时间点,任何抗癫痫发作药物影响的证据非常不确定。
证据类型、等级与局限
- 证据类型:系统评价与贝叶斯网络Meta分析,采用GRADE方法评级;苯妥英与左乙拉西坦为中等确定性,卡马西平与丙戊酸为非常低确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为苯妥英或左乙拉西坦可降低成人创伤性脑损伤患者的早期癫痫发作风险。
- 作者指出需进一步研究评估所需疗程与长期安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We sought to evaluate the effectiveness of any antiseizure medication on the incidence of early post-traumatic seizures among adult patients with traumatic brain injury.
DATA SOURCES: MEDLINE, Embase, PubMed, Cochrane Central Register of Controlled Trials, and LILACS were searched from inception to October 2023.
STUDY SELECTION: We included randomized trials of adult patients with traumatic brain injury evaluating any antiseizure medication compared with either placebo or another agent.
DATA EXTRACTION: Two reviewers independently extracted individual study data and evaluated studies for risk of bias using the Cochrane Risk of Bias tool. Our main outcome of interest was the occurrence of early seizures (i.e., within 7 d); secondary outcomes included late-seizures and all-cause mortality.
DATA SYNTHESIS: Bayesian network meta-analyses were used to derive risk ratios (RRs) alongside 95% credible intervals (CrIs). We used Grading of Recommendations Assessment, Development, and Evaluation methodology to rate the certainty in our findings. Overall, ten individual randomized controlled trials (1851 participants) were included. Compared with placebo, phenytoin (RR, 0.28; 95% CrI, 0.13-0.57; moderate certainty) and levetiracetam (RR, 0.20; 95% CrI, 0.07-0.60; moderate certainty) were associated with a reduction in the risk of early seizures. Carbamazepine may be associated with a reduced risk of early seizures, but the evidence is very uncertain (RR, 0.41; 95% CrI, 0.12-1.27; very low certainty). Valproic acid may result in little to no difference in the risk of early seizures, but the evidence is very uncertain (RR, 0.97; 95% CrI, 0.16-9.00; very low certainty). The evidence is very uncertain about the impact of any antiseizure medication on the risk of late seizures or all-cause mortality at longest reported follow-up time.
CONCLUSIONS: Phenytoin or levetiracetam reduce the risk of early seizures among adult patients with traumatic brain injury. Further research is needed to evaluate required duration of therapy and long-term safety profiles.
参考来源
- Angriman F, Taran S, Angeloni N, et al. Antiseizure Medications in Adult Patients With Traumatic Brain Injury: A Systematic Review and Bayesian Network Meta-Analysis. Crit Care Explor. 2024. PMID: 39324956. doi:10.1097/CCE.0000000000001160
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。